About Regeneron Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Address: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Regeneron Pharmaceuticals, Inc News and around…
Latest news about Regeneron Pharmaceuticals, Inc (REGN) common stock and company :
ICU physician Dr. Lakshman Swamy, from Cambridge Health Alliance and Boston Medical Center, speaks on Yahoo Finance Live about the new reports of a surge in cases involving COVID-19. and importance of vaccines.
Yahoo Finance's Seana Smith details some headlines that we are watching on Friday.
Dr. Amesh A. Adalja MD, a senior scholar at the Johns Hopkins Center for Health Security, joins Yahoo Finance Live to discuss the newly discovered COVID-19 variant and the potential implications based on what is currently known.
Stock market futures dropped on Friday amid uncertainty about a newly discovered COVID-19 variant.
Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 12...
The industry potentially faces a significant expansion of government regulation despite success in watering down Democratic proposals in the social-spending and climate bill.
Meylin Andares helped increase the applicant pool for Black and Latino students by nearly 45% during the 10 years she spent recruiting for the University at Albany, her alma mater. Then a phone call from her best friend, who is part of the legal team at Regeneron Pharmaceuticals in North Greenbush, prompted Andares to pursue a newly created position for the drug developer’s manufacturing and product supply team: director of diversity, equity and inclusion. Within a month, Andares finished her master’s degree in higher education administration from Stony Brook University.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.
Novavax sees its Relative Strength Rating reach the 80-plus level.
Former U.S. Commerce Secretary and Former Washington Governor Gary Locke joins Yahoo Finance Live to discuss travel warnings to Germany and Denmark as COVID-19 cases are rising, the push get more vaccinated in developing countries, and the impact of Trump's tariffs on Chinese goods.
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.
Regeneron Pharmaceuticals Inc(NASDAQ: REGN) hasextended the research term of its collaborationwithDecibel ...
The therapy will likely face stiff competition from more convenient COVID-19 pills.
The company's financial results are rebounding from their pandemic lows.
Investors wanted more details from the company's latest clinical results.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic ...
Dr. James Simmons, Hospitalist Nurse Practitioner joins Yahoo Finance’s Alexis Christoforous to discuss on holiday gatherings amid rising COVID-19 cases and the potential "double whammy" amid flu season.
Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.
Its future is full of question marks.
A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value.
Emergency Medicine Physician Dr. Hiral Tipirneni speaks with Yahoo Finance’s Alexis Christoforous and Karina Mitchell about how Americans must still take precautions when spending their holidays indoors with family amid the ongoing pandemic.
Drug approvals for Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.
Sellers of monoclonal antibodies have seen their share prices take a hit since Merck and Pfizer announced positive data on Covid-19 antiviral pills.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
NewYork Presbyterian Hospital CEO Dr. Steven Corwin joins Yahoo Finance to discuss the latest related to booster shots against COVID-19.
A Relative Strength Rating upgrade for Regeneron Pharmaceutical shows improving technical performance. Will it continue?
Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.
Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are ...
Some of the stocks that may grab investor focus today are: Wall Street expects Warner Music Group Corp. (NYSE: WMG) to report ...